01
Heart & Cardiovascular
Apo-B, Lp(a), LDL particle number, homocysteine, lipid sub-fractions.
The science · Long read
Blood, read asa system.
Merios turns 160+ blood biomarkers into a single composite score and a biological-age estimate, grounded in the preventive-medicine literature. This page is the full argument — the model, the markers and the references. No clinician has reviewed it yet.
- Markers
- 160+
- Pillars
- 4
- Clinicians
- Not yet
- Updated
- Oct 2026
01 · Thesis
A biomarker in isolation is almost always misleading.
The signal lives in the system — in convergence, trajectory, and time. A single composite is how clinicians already think; it is how consumer health finally should.
Why single markers fail.
A normal LDL with a high Apo-B is not normal. An in-range HbA1c with elevated fasting insulin is not in range. Reference intervals are defined against a population that is itself largely metabolically unwell1— so normal flags are a low bar, not a goal.
Why a composite works.
Composite indices reduce noise, capture system-level risk, and track meaningful change over time. They are the statistical spine of landmark work on biological age and cardiometabolic risk stratification2. Merios is built on that foundation.
03 · The Blood pillarEleven blood systems,
Eleven blood systems,
one composite signal.
Within the Blood pillar, Merios reads eleven biomarker systems the way a clinician reads a panel — as a network, not a list.
- 02
Metabolism & Glucose
Fasting glucose, HbA1c, fasting insulin, HOMA-IR, C-peptide.
- 03
Inflammation & Immunity
hs-CRP, IL-6, ferritin, fibrinogen, WBC differential, neutrophil-lymphocyte ratio.
- 04
Hematology
Full CBC, RBC indices (MCV, MCH, RDW), hemoglobin, platelet count.
- 05
Liver
ALT, AST, GGT, ALP, total and direct bilirubin, albumin, total protein.
- 06
Kidney & Electrolytes
Creatinine, cystatin-C, eGFR, urea, sodium, potassium, chloride, uric acid.
- 07
Hormonal
Testosterone (total and free), estradiol, SHBG, DHEA-S, cortisol, prolactin.
- 08
Thyroid
TSH, free T4, free T3, reverse T3, anti-TPO, anti-thyroglobulin antibodies.
- 09
Vitamins & Minerals
25-OH Vitamin D, B12, folate, magnesium, zinc, selenium, iron panel.
- 10
Performance & Recovery
Creatine kinase, lactate, omega-3 index, IGF-1, vitamin D status.
- 11
Autoimmune & Systemic
ANA, anti-CCP, rheumatoid factor, complement (C3/C4), ESR.
03 · The model
Four pillars, one score.
Every marker is weighted inside a pillar; pillars aggregate into a single composite on a 0–100 scale. The pillars are designed to be independently auditable so clinicians can see exactly where the score comes from.
04 · Biological age
The number you can actually move.
Merios estimates biological age from a validated subset of the panel, inspired by the Levine PhenoAge framework3. The delta — chronological minus biological — is a tractable target: most markers respond to intervention within 90 days.
Chronological
Years, calendar
Biological
Years, estimated — illustrative
Delta · percentile
Top 18% in cohort — illustrative band
05 · Clinical review
Clinical review: not done yet.
As of October 2026, no practising clinician has reviewed the methodology, thresholds or literature base of Merios. We’re recruiting reviewers; their names and the date of their review will be published here once it’s done. Until then, Merios is a wellness tool, not a medical device.
Clinical reviewers, seats open
Recruiting — 2026
We're looking for practising clinicians and researchers to review Merios's scoring rules, reference intervals and methodology. Their names and the date of each review will be published here once a review is done.
Merios
06 · References
Literature informing the model.
An editorial selection — not an exhaustive bibliography. Numbers match the superscripts used throughout this page.
Rose G. Sick individuals and sick populations. International Journal of Epidemiology (1985).
Sniderman A. D. et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiology (2019).
Levine M. E. et al. An epigenetic biomarker of aging for lifespan and healthspan (PhenoAge). Aging (2018).
Lauer M. S., D'Agostino R. B. The randomized registry trial — the next disruptive technology in clinical research? New England Journal of Medicine (2013).
Taddei S. et al. Inflammation, oxidative stress, and endothelial dysfunction in cardiometabolic disease. The Lancet (2019).
Després J.-P. Body fat distribution and risk of cardiovascular disease: an update. Circulation (2012).
Horvath S. DNA methylation age of human tissues and cell types. Genome Biology (2013).
Ridker P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). New England Journal of Medicine (2017).